FDA grants approval to Axsome Therapeutics’ migraine medication containing Betadex Sulfobutylether Sodium
The U.S. Food and Drug Administration has approved Axsome Therapeutics’ new migraine treatment tablet on 30 January 2025 [1]. Marketed
Tag: rizatriptan
Axsome Therapeutics’ betadex sulfobutylether sodium containing composition: FDA Acceptance of NDA Resubmission
Axsome Therapeutics, Inc., an U.S.-based biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS)